# US 7,745,157 B2 · Human lymphocyte medium adjuvant

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,745,157 B2
- Document ID: US7745157B2
- Status: Granted
- Kind: B2
- Application number: 10/783,259
- Filed: 2004-02-20
- Published: 2004-12-02
- Granted: 2010-06-29
- Earliest claimed: 2003-02-21
- Assignees: University of Maryland, Baltimore; Hasumi LLC
- Inventors: Kenichiro Hasumi; Dean LeMar Mann; Kim Graulich Hankey; Kristina Michelle Holt
- Web page: https://patentgrep.com/patent/US7745157B2

## CPC

- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 31/04: Antibacterial agents
- A61P 31/14: for RNA viruses
- A61P 31/18: for HIV
- A61P 31/20: for DNA viruses
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61K 2039/55588: {Adjuvants of undefined constitution}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to an adjuvant derived from human lymphocytes. The adjuvant can be used in combination with traditional vaccines or cancer immunotherapy, to enhance the response of the patient's immune system to the vaccine or other immunotherapeutic agent. The adjuvant is derived from the supernatant collected from cultured activated lymphocytes.

## Claims

### Claim 1

A method of enhancing an immune response to an antigen in a mammal, comprising co-administering lymphocyte conditioned medium comprised of products generated from pooled samples of peripheral blood mononuclear cells activated with anti-CD3- and anti-CD28-coated beads and an antigen, wherein said co-administration facilitates and enhances dendritic cell maturation and antigen-presenting cell function which results in enhanced immunologic responses to the co-administered antigen in the mammal.

### Claim 2 (depends on 1)

The method of claim 1, wherein said antigen is HIV-1 or HIV-2.

### Claim 3 (depends on 1)

The method of claim 1, wherein said antigen is hepatitis-B.

### Claim 4 (depends on 1)

The method of claim 1, wherein said antigen is tetanus toxoid.

### Claim 5 (depends on 1)

The method of claim 1, wherein said antigen is prostate-specific antigen.

### Claim 6 (depends on 1)

The method of claim 1, wherein said antigen is hepatitis-A.

### Claim 7 (depends on 1)

The method of claim 1, wherein said antigen is diptheria.

### Claim 8 (depends on 1)

The method of claim 1, wherein the dosage of said lymphocyte conditioned medium is about 10 μg to about 500 μg.

### Claim 9 (depends on 1)

The method of claim 1, wherein said administration is selected from the group consisting of intracutaneous, subcutaneous and intramuscular injection and combinations thereof.

### Claim 10 (depends on 1)

The method of claim 1, wherein said administration is selected from the group consisting of weekly, biweekly, monthly, and yearly and combinations thereof.

### Claim 11

A method of enhancing an immune response to an antigen in a mammal, comprising administering to the mammal a vaccine comprising an antigen and lymphocyte conditioned medium comprised of products generated from pooled samples of peripheral blood mononuclear cells activated with anti-CD3- and anti-CD28-coated beads, wherein the administration of the vaccine facilitates and enhances dendritic cell maturation and antigen-presenting cell function which results in enhanced immunologic responses to the antigen in the mammal.